Neuroendocrine Tumors
Conditions
Keywords
Novaferon, Recombinant anti-tumor and anti-virus protein for injection, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
Brief summary
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor and anti-virus protein for injection in treating patients with advanced neuroendocrine tumors who have failed standard treatment or are unable to receive standard treatment.
Detailed description
This is a Phase Ⅱ exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor and anti-virus protein for injection in treating patients with advanced neuroendocrine tumors who have failed standard treatment or are unable to receive standard treatment. Recombinant anti-tumor and anti-virus protein for injection, 10μg,im,3 times for the first week, followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week. Treatment continued until the patient died or had unacceptable toxicity or had disease progression or required to discontinue the treatment. At the time of disease progression, if investigators believe patients can continue to benefit from the investigational product, patients may be provided with recombinant anti-tumor and anti-virus protein for injection,but only survival follow-up datas will be recorded.
Interventions
DRUGRecombinant anti-tumor and anti-virus protein for injection (Novaferon)
Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
Sponsors
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have been fully aware of the study and voluntarily signed the informed consent. * At least 18 years old. * Have a confirmed histological or cytological diagnosis of low- or intermediate-grade advanced NETs (unresectable or metastatic), the pathology must meet one of the following criteria: (a) primary site of lung or thymus (carcinoid) with mitotic count of ≤ 10/10 High Power Field \[HPF\]) (b) other primary site (including primary unknown) with mitotic count of ≤ 20/10 High Power Field \[HPF\] and Ki67 index of ≤ 20%，or with Ki67 index of \> 20% and well-differentiated. * Patients who have failed standard treatment or are unable to receive standard treatment, and have disease progression within the past 12 months; * At least one measurable lesion according to the RECIST 1.1 criteria that has not been previously locally treated. * ECOG performance status 0, 1 or 2. * Minimum of 4 weeks since any local radiotherapy or surgery for the control of symptoms or severe complications(local radiotherapy for the control of bone metastases is not the limit)，and adequately recovered from toxicities of any prior therapy). * Life expectancy of at least 3 months.
Exclusion criteria
* Prior treatment with Recombinant Anti-tumor and Anti-virus Protein for Injection. * Prior treatment with Interferon. * Pregnancy or breast-feeding women or women who may be pregnant were positive drug test before administration. * Patient of child-bearing potential(male or less than 1 year postmenopausal women) were reluctant to take contraceptive measures. * Patient who were allergic to Interferon-α or who had interferon-α antibody. * Have brain metastases or previous history of brain metastases or history of seizures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | 1 year | PFS is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress. |
| Disease control rate(DCR) | 1 year | DCR is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate(ORR) | 1 year | ORR is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments. |
| Overall survival (OS) | 3 years | OS is defined as the length of time from random assignment to death or to last contact |
| Adverse Events(AEs) | 1 year | AEs are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. |
Countries
China
Contacts
Primary ContactXu Jianming, M.D.
Outcome results
None listed